Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2

por Vormoor, Britta, Schlosser, Yvonne T., Blair, Helen, Sharma, Abhishek, Wilkinson, Sarah, Newell, David R., Curtin, Nicola
Publicado 2017

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

por Chen, Lindi, Rousseau, Raphaël F., Middleton, Steven A., Nichols, Gwen L., Newell, David R., Lunec, John, Tweddle, Deborah A.
Publicado 2015

The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [(18)F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

por Haagensen, Emma J., Thomas, Huw D., Wilson, Ian, Harnor, Suzannah J., Payne, Sara L., Rennison, Tommy, Smith, Kate M., Maxwell, Ross J., Newell, David R.
Publicado 2013

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation

por Lochhead, Pamela A., Clark, Jonathan, Wang, Lan-Zhen, Gilmour, Lesley, Squires, Matthew, Gilley, Rebecca, Foxton, Caroline, Newell, David R., Wedge, Stephen R., Cook, Simon J.
Publicado 2016

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037

por Haagensen, Emma J., Thomas, Huw D., Schmalix, Wolfgang A., Payne, Andrew C., Kevorkian, Lara, Allen, Rodger A., Bevan, Paul, Maxwell, Ross J., Newell, David R.
Publicado 2016

Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases

por Reuillon, Tristan, Alhasan, Sari F., Beale, Gary S., Bertoli, Annalisa, Brennan, Alfie, Cano, Celine, Reeves, Helen L., Newell, David R., Golding, Bernard T., Miller, Duncan C., Griffin, Roger J.
Publicado 2016

Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

por Matheson, Elizabeth C., Thomas, Huw, Case, Marian, Blair, Helen, Jackson, Rosanna K., Masic, Dino, Veal, Gareth, Halsey, Chris, Newell, David R., Vormoor, Josef, Irving, Julie A.E.
Publicado 2019

Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma

por Alhasan, Sari F, Haugk, Beate, Ogle, Laura F, Beale, Gary S, Long, Anna, Burt, Alastair D, Tiniakos, Dina, Televantou, Despina, Coxon, Fareeda, Newell, David R, Charnley, Richard, Reeves, Helen L
Publicado 2016

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer

por Beale, Gary, Haagensen, Emma J, Thomas, Huw D, Wang, Lan-Zhen, Revill, Charlotte H, Payne, Sara L, Golding, Bernard T, Hardcastle, Ian R, Newell, David R, Griffin, Roger J, Cano, Celine
Publicado 2016

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

por Chen, Lindi, Pastorino, Fabio, Berry, Philip, Bonner, Jennifer, Kirk, Calum, Wood, Katrina M., Thomas, Huw D., Zhao, Yan, Daga, Antonio, Veal, Gareth J., Lunec, John, Newell, David R., Ponzoni, Mirco, Tweddle, Deborah A.
Publicado 2019

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions

por Blackburn, Tim J., Ahmed, Shafiq, Coxon, Christopher R., Liu, Junfeng, Lu, Xiaohong, Golding, Bernard T., Griffin, Roger J., Hutton, Claire, Newell, David R., Ojo, Stephen, Watson, Anna F., Zaytzev, Andrey, Zhao, Yan, Lunec, John, Hardcastle, Ian R.
Publicado 2013

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

por Drummond, Catherine J., Esfandiari, Arman, Liu, Junfeng, Lu, Xiaohong, Hutton, Claire, Jackson, Jennifer, Bennaceur, Karim, Xu, Qing, Makimanejavali, Aditya Rao, Bello, Fabio Del, Piergentili, Alessandro, Newell, David R., Hardcastle, Ian R., Griffin, Roger J., Lunec, John
Publicado 2016

Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer

por Coffey, Kelly, Blackburn, Timothy J., Cook, Susan, Golding, Bernard T., Griffin, Roger J., Hardcastle, Ian R., Hewitt, Lorraine, Huberman, Kety, McNeill, Hesta V., Newell, David R., Roche, Celine, Ryan-Munden, Claudia A., Watson, Anna, Robson, Craig N.
Publicado 2012

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase

por Matheson, Christopher J., Coxon, Christopher R., Bayliss, Richard, Boxall, Kathy, Carbain, Benoit, Fry, Andrew M., Hardcastle, Ian R., Harnor, Suzannah J., Mas-Droux, Corine, Newell, David R., Richards, Mark W., Sivaprakasam, Mangaleswaran, Turner, David, Griffin, Roger J., Golding, Bernard T., Cano, Céline
Publicado 2020

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

por Johnson, Neil, Li, Yu-Chen, Walton, Zandra E., Cheng, Katherine A., Li, Danan, Rodig, Scott J., Moreau, Lisa A., Unitt, Christine, Bronson, Roderick T., Thomas, Huw D., Newell, David R., D’Andrea, Alan D., Curtin, Nicola J., Wong, Kwok-Kin, Shapiro, Geoffrey I.
Publicado 2011

Structure-guided design of purine-based probes for selective Nek2 inhibition

por Coxon, Christopher R., Wong, Christopher, Bayliss, Richard, Boxall, Kathy, Carr, Katherine H., Fry, Andrew M., Hardcastle, Ian R., Matheson, Christopher J., Newell, David R., Sivaprakasam, Mangaleswaran, Thomas, Huw, Turner, David, Yeoh, Sharon, Wang, Lan Z., Griffin, Roger J., Golding, Bernard T., Cano, Céline
Publicado 2016

Identification and Characterization of an Irreversible Inhibitor of CDK2

por Anscombe, Elizabeth, Meschini, Elisa, Mora-Vidal, Regina, Martin, Mathew P., Staunton, David, Geitmann, Matthis, Danielson, U. Helena, Stanley, Will A., Wang, Lan Z., Reuillon, Tristan, Golding, Bernard T., Cano, Celine, Newell, David R., Noble, Martin E.M., Wedge, Stephen R., Endicott, Jane A., Griffin, Roger J.
Publicado 2015

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

por Coxon, Christopher R., Anscombe, Elizabeth, Harnor, Suzannah J., Martin, Mathew P., Carbain, Benoit, Golding, Bernard T., Hardcastle, Ian R., Harlow, Lisa K., Korolchuk, Svitlana, Matheson, Christopher J., Newell, David R., Noble, Martin E. M., Sivaprakasam, Mangaleswaran, Tudhope, Susan J., Turner, David M., Wang, Lan Z., Wedge, Stephen R., Wong, Christopher, Griffin, Roger J., Endicott, Jane A., Cano, Céline
Publicado 2016

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

por Willoughby, Catherine E., Jiang, Yanyan, Thomas, Huw D., Willmore, Elaine, Kyle, Suzanne, Wittner, Anita, Phillips, Nicole, Zhao, Yan, Tudhope, Susan J., Prendergast, Lisa, Junge, Gesa, Lourenco, Luiza Madia, Finlay, M. Raymond V., Turner, Paul, Munck, Joanne M., Griffin, Roger J., Rennison, Tommy, Pickles, James, Cano, Celine, Newell, David R., Reeves, Helen L., Ryan, Anderson J., Wedge, Stephen R.
Publicado 2019

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor

por Miller, Duncan C., Reuillon, Tristan, Molyneux, Lauren, Blackburn, Timothy, Cook, Simon J., Edwards, Noel, Endicott, Jane A., Golding, Bernard T., Griffin, Roger J., Hardcastle, Ian, Harnor, Suzannah J., Heptinstall, Amy, Lochhead, Pamela, Martin, Mathew P., Martin, Nick C., Myers, Stephanie, Newell, David R., Noble, Richard A., Phillips, Nicole, Rigoreau, Laurent, Thomas, Huw, Tucker, Julie A., Wang, Lan-Zhen, Waring, Michael J., Wong, Ai-Ching, Wedge, Stephen R., Noble, Martin E. M., Cano, Celine
Publicado 2022